Cue Biopharma, Inc. (CUE)

Cue Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	43.87	51.36	54.88	67.24	77.59	47.01
Short-Term Investments	0	0	24.68	0	10	15.12
Cash & Cash Equivalents	43.87	51.36	79.56	67.24	87.59	62.13
Cash Growth	-36.58%	-35.45%	18.31%	-23.23%	40.97%	54.27%
Receivables	1.4	1.7	0.06	3.14	1.42	0.75
Other Current Assets	-0.6	-1.6	-2.43	-1.92	-1.48	-1.86
Total Current Assets	44.67	51.45	77.19	68.47	87.53	61.02
Property, Plant & Equipment	6.33	7.12	10.7	11.92	8.88	7.18
Other Long-Term Assets	2.96	2.96	3.39	3.01	3.12	3.4
Total Long-Term Assets	9.28	10.08	14.1	14.93	12.01	10.58
Total Assets	53.95	61.53	91.28	83.4	99.53	71.61
Accounts Payable	3.92	3.5	2.73	2.59	2.07	0.88
Current Debt	7.17	7.33	5.26	4.93	4.78	4.45
Other Current Liabilities	7	6.25	3.55	5.27	9.47	6.32
Total Current Liabilities	18.09	17.08	11.55	12.79	16.32	11.66
Long-Term Debt	5.82	7.36	14.05	5.12	2.37	1.35
Other Long-Term Liabilities	0	0	0	0	1.94	4.02
Total Long-Term Liabilities	5.82	7.36	14.05	5.12	4.31	5.37
Total Liabilities	23.91	24.45	25.6	17.91	20.62	17.02
Total Debt	13	14.7	19.32	10.05	7.15	5.8
Debt Growth	-30.52%	-23.92%	92.14%	40.67%	23.30%	-
Retained Earnings	-313.54	-301.19	-250.46	-197.45	-153.29	-108.5
Comprehensive Income	0	0	-0.1	0	0.01	-0.01
Shareholders' Equity	30.04	37.09	65.68	65.49	78.91	54.58
Net Cash / Debt	30.87	36.66	60.24	57.19	80.44	56.34
Net Cash / Debt Growth	-38.83%	-39.14%	5.33%	-28.91%	42.79%	39.88%
Net Cash Per Share	0.62	0.80	1.69	1.83	2.80	2.56
Working Capital	26.58	34.37	65.64	55.68	71.21	49.37
Book Value Per Share	0.61	0.81	1.84	2.09	2.75	2.48

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).